
Triple Agonist
Researchers are investigating multi-agonist peptides that interact with GLP-1, GIP, and glucagon receptors to better understand appetite signaling, glucose regulation, and energy metabolism. These compounds remain investigational and are not approved by the FDA for general use.
Current Research Areas
- Appetite and satiety signaling
- Glucose regulation and metabolic markers
- Body composition under clinical supervision
Is Triple Agonist FDA-approved?+
No. Multi-agonist peptides for metabolic use are investigational and not FDA-approved. A licensed clinician can discuss whether any evidence-based option is appropriate during a consultation.
How do I learn whether this is appropriate for me?+
Schedule a consultation. If peptide therapy may be relevant, an appropriately licensed medical provider reviews your history, goals, and labs to determine candidacy.

